Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression

International Journal of Oncology

Volumn 34, Issue 5, 2009, Pages 1291-1301

  Wong, Lee Lee ^a   Chang, Chan Fong ^a   Koay, Evelyn S C ^a,b   Zhang, Daohai ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Breast cancer; HER 2 neu; PI3K p38MAPK; Protein phosphatase 2A; Tyrosine phosphorylation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; CASPASE 3; CASPASE 4; CRK LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EZRIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOD PROTEIN; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR ALPHA 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE SYK; PROTEIN SHC; RECEPTOR FOR ACTIVATED C KINASE 1; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEUREGULIN-1; PHOSPHORYLATION; PROGNOSIS; PROTEIN PHOSPHATASE 2; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 67649440555     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000256     Document Type: Article

References (40)

1. Reese DM and Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15: 1-8, 1997.
2. Holbro T, Civenni G and Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99-110, 2003.
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 235: 177-182, 1987.
4. Spector NL, Xia W, Burris H, et al: Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumour growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23: 2502-2512, 2005.
5. Grant S, Qiao L and Dent P: Roles of ERBB family receptor tyrosine kinases, and downstream signalling pathways, in the control of cell growth and survival. Front Biosci 7: D376-D389, 2002.
6. Mukherji M, Brill LM, Ficarro SB, Hampton GM and Schultz PG: A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signalling pathways. Biochemistry 45: 15529-15540, 2006.
7. Bose R, Molina H, Patterson AS, et al: Phosphoproteomic analysis of HER2/neu signalling and inhibition. Proc Natl Acad Sci USA 103: 9773-9778, 2006.
8. Friedman DB, Wang SE, Whitwell CW, Caprioli RM and Arteaga CL: Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signalling. Mol Cell Proteomics 6: 150-169, 2007.
9. Wolf-Yadlin A, Kumar N, Zhang Y, et al: Effects of HER2 overexpression on cell signalling networks governing proliferation and migration. Mol Syst Biol 2: 54, 2006.
10. Kumar N, Wolf-Yadlin A, White FM and Lauffenburger DA: Modeling HER2 effects on cell behaviour from mass spectrometry phosphotyrosine data. PLoS Comput Biol 3: E4, 2007.
11. Zhang D, Tai LK, Wong LL, et al: Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4: 1686-1696, 2005.
12. Wallasch C, Weiss FU, Niederfellner G, et al: Heregulindependent regulation of HER2/neu oncogenic signalling by heterodimerization with HER3. EMBO J 14: 4267-4275, 1995.
13. Dankort D, Jeyabalan N, Jones N, Dumont DJ and Muller WJ: Multiple ErbB-2/neu phosphorylation sites mediate transformation through distinct effector proteins. J Biol Chem 276: 38921-38928, 2001.
14. Janssens V and Goris J: Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439, 2001
15. Schönthal AH: Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett 170: 1-13, 2001.
16. Abraham D, Podar K, Pacher M, et al: Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275: 22300-22304, 2000.
17. Andrabi S, Gjoerup OV, Kean JA, Roberts TM and Schaffhausen B: Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci USA 104: 19011-19016, 2007.
18. Chen J, Parsons S and Brautigan DL: Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem 269: 7957-7962, 1994.
19. Tsai CM, Levitzki A, Wu LH, et al: Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 56: 1068-1074, 1996.
20. Bulavin DV and Fornace AJ: p38 MAP kinase's emerging role as a tumour suppressor. Adv Cancer Res 92: 95-118, 2004.
21. Aguirre-Ghiso JA, Estrada Y, Liu D and Ossowski L: ERK (MAPK) activity as a determinant of tumour growth and dormancy; regulation by p38(SAPK). Cancer Res 63: 1684-1695, 2003.
22. Zhang D, Tai LK, Wong LL, et al: Proteomic characterization of differentially expressed proteins in breast cancer: Expression of hnRNP H1, RKIP and GRP78 is strongly associated with HER-2/neu status. Proteomics Clin Appl 2: 99-107, 2008.
23. Gembitsky DS, Lawlor K, Jacovina A, Yaneva M and Tempst P: A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. Mol Cell Proteomics 3: 1102-1118, 2004.
24. Matsuyoshi S, Shimada K, Nakamura M, Ishida E and Konishi N: FADD phosphorylation is critical for cell cycle regulation in breast cancer cells. Br J Cancer 94: 532-539, 2006.
25. Koseki T, Inohara N, Chen S and Nunez G: ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA 95: 5156-5160, 1998.
26. Ekhterae D, Lin Z, Lundberg MS, et al: ARC inhibits cytochrome c release from mitochondria and protects against hypoxia-induced apoptosis in heart-derived H9c2 cells. Circ Res 85: E70-E77, 1999.
27. Hong YM, Jo DG, Lee JY, et al: Down-regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia. FEBS Lett 543: 170-173, 2003.
28. Bretscher A: Regulation of cortical structure by the ezrinradixin-moesin protein family. Curr Opin Cell Biol 11: 109-116, 1999.
29. Gautreau A, Poullet P, Louvard D and Arpin M: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 7300-7305, 1999.
30. Sarrió D, Rodriguez-Pinilla SM, Dotor A, et al: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 98: 71-79, 2006.
31. Favre B, Zolnierowicz S, Turowski P and Hemmings BA: The catalytic subunit of protein phosphatase 2A is carboxylmethylated in vivo. J Biol Chem 269: 16311-16317, 1994.
32. Kong M, Fox CJ, Mu J, et al: The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science 306: 695-698, 2004.
33. Grethe S and Pörn-Ares MI: p38 MAPK regulates phosphorylation of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-alpha induced endothelial apoptosis. Cell Signal 18: 531-540, 2006.
34. Xin M and Deng X: Protein phosphatase 2A enhances the proapoptotic function of Bax through dephosphorylation. J Biol Chem 281: 18859-18867, 2006.
35. Sontag JM and Sontag E: Regulation of cell adhesion by PP2A and SV40 small tumor antigen: an important link to cell transformation. Cell Mol Life Sci 63: 2979-2991, 2006.
36. Janssens V, Goris J and Van Hoof C: PP2A: the expected tumour suppressor. Curr Opin Genet Dev 15: 34-41, 2005.
37. Ratcliffe MJ, Itoh K and Sokol SY: A positive role for the PP2A catalytic subunit in Wnt signal transduction. J Biol Chem 275: 35680-35683, 2000.
38. Yan Y and Mumby MC: Distinct roles for PP1 and PP2A in phosphorylation of the retinoblastoma protein. PP2A regulates the activities of G(1) cyclin-dependent kinases. J Biol Chem 274: 31917-31924, 1999.
39. Schweyer S, Bachem A, Bremmer F, et al: Expression and function of protein phosphatase PP2A in malignant testicular germ cell tumours. J Pathol 213: 72-81, 2007.
40. Gopalakrishna R, Gundimeda U, Fontana JA and Clarke R: Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status. Cancer Lett 136: 143-151, 1999.